<DOC>
	<DOCNO>NCT02249013</DOCNO>
	<brief_summary>This phase II open label , single arm clinical trial safety efficacy explore short-course regimen intra-operative Hyperthermic Intraperitoneal Chemotherapy ( HIPEC ) upfront therapy patient advance Epithelial Ovarian Cancer ( EOC ) undergo Cytoreductive Surgery ( CRS ) .</brief_summary>
	<brief_title>Cytoreductive Surgery Hyperthermic Intraperitoneal Chemotherapy Ovarian Cancer</brief_title>
	<detailed_description>The purpose study evaluate efficacy safety protocol hypothesis may improve patient survival low rate morbidity mortality . In setting , CRS follow short-course regimen intra-operative HIPEC upfront therapy patient stage III-IV EOC . Advanced CRS perform standard peritonectomy procedure visceral resection direct towards complete elimination tumor abdominopelvic cavity . HIPEC perform accord closed-abdomen technique use cisplatin ( 25 mg/L perfusate/m2 , total limit 240mg ) 30 minute , intra-abdominal target temperature 41-43Â°C . Perfusate ( 2L/m2 , range 4L 6L ) circulate use extracorporeal circulation device ( Performer HT ; RAND , Medolla , Italy ) flow rate 700 ml/min . Systemic chemotherapy include standard combination carboplatin paclitaxel adjuvant neo-adjuvant plus adjuvant regimen .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Patients previous treatment candidate elective surgery histological diagnosis epithelial ovarian carcinoma ; clinical stage IIIB IV , without suspicion extraabdominal metastasis ; age 18 70 year ; performance status 02 ( ECOG , Eastern Cooperative Oncology Group ) / great 70 point Karnofsky scale ; appropriate cardiorespiratory , hepatorenal hematological reserve ; sign Consent Form . Evidence extensive retroperitoneal lymph node disease ; limit obesity ; apparent confirm uncontrolled infection ; limit comorbidities ; malignancy activity ; previous radiation chemotherapy treatment ( except neoadjuvant chemotherapy study protocol ) major abdominal surgery ; neuropsychiatric disorder ; history drug allergy ; pregnancy breast feeding . Still , consider HIPEC protocol patient unresectable disease ( presence invasive peritoneal implant inoperable high risk resection critical location hepatic hilum , mesenteric root , trunk celiac , mesentery , several small implant serosa small intestine ) / residual disease cytoreduction great equal 2.5 mm ( CC2 CC3 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Ovarian Cancer</keyword>
</DOC>